Malignant fibrous histiocytoma of bone: A survival analysis from the National Cancer Database

Abstract

Background and Objectives: Malignant fibrous histiocytoma (MFH) of bone, now known as undifferentiated pleomorphic sarcoma of bone, is a rare neoplasm that accounts for less than 2% of all primary malignant bone tumors. The objective of the current study was to evaluate prognosis and survival for MFH of bone. Methods: The 2004 to 2016 National Cancer Database was queried to identify patients with a primary MFH of bone. Kaplan-Meier survival and Cox regression analyses were used to analyze overall survival and risk factors associated with overall mortality. Results: The overall 5-year and 10-year survival rates were 38.3% and 30.5%, respectively. Increasing stage and metastatic disease at presentation were associated with poor overall survival (P < .001). Patients aged 18 to 50 years (hazard ratio [HR], 0.51), 51 to 75 years (HR, 0.61), and those undergoing surgery (HR, 0.39) had improved survival. Having Medicare insurance (HR, 1.48), residing in a low educated area (HR, 2.56), and positive surgical margins (HR, 1.80) were associated with poor survival. Conclusions: The overall prognosis of MFH of bone is poor with a reported 5-year survival rate of 38.3%. Undergoing surgery and younger age were associated with a better prognosis. Older age, having Medicare insurance, and positive surgical margins were predictors of mortality. K E Y W O R D S bone sarcoma, malignant fibrous histiocytoma, MFH, NCDB, survival, undifferentiated pleomorphic sarcoma, UPS 2.1 | Database and patient selection

Undifferentiated pleomorphic sarcoma of the extremity and trunk: a retrospective cohort study of 166 cases in a large institution

“…Related reports suggest that the recurrence rate of UPS is greater than 31% ( 13 ). Compared with other STSs, the 5-year overall survival (OS) rate is lower in UPS, around 50–70% ( 9 , 14 - 16 ), and some studies revealed that the 5-year OS rate could be 72% ( 17 ). Surgical treatment is largely followed in the UPS ( 16 , 18 ), which can achieve significantly local control for primary UPS.…”

“…Compared with other STSs, the 5-year overall survival (OS) rate is lower in UPS, around 50–70% ( 9 , 14 - 16 ), and some studies revealed that the 5-year OS rate could be 72% ( 17 ). Surgical treatment is largely followed in the UPS ( 16 , 18 ), which can achieve significantly local control for primary UPS. Forty percent of patients with these tumors develop pulmonary metastases ( 15 ), which was with 8–12 months of median survival ( 19 ).…”

Undifferentiated Pleomorphic Sarcoma of the Spine in a patient with Li-Fraumeni syndrome: a case report

“…Many studies have shown that advanced age is an independent risk factor for poor prognosis [26,27]. Lou et al [3]revealed that an age ≥ 55 years were independently associated with poor overall survival in spinal UPS.…”

Undifferentiated Pleomorphic Sarcoma of the Extremity and Trunk: A Retrospective Cohort Study of 166 Cases in a Large Institution

“…Related reports suggest that the recurrence rate of UPS is greater than 31% [12]. Compared with other STSs, the 5-year survival rate is lower in UPS, around 50-70% [9,[13][14][15], and some studies revealed that the 5-years OS rate could reach 72% [16]. Surgical treatment is largely followed in the UPS [15,17], which can achieve signi cantly local control for primary UPS.…”

“…Compared with other STSs, the 5-year survival rate is lower in UPS, around 50-70% [9,[13][14][15], and some studies revealed that the 5-years OS rate could reach 72% [16]. Surgical treatment is largely followed in the UPS [15,17], which can achieve signi cantly local control for primary UPS. 40% of patients with these tumors develop pulmonary metastases [14], which was with 8-12 months of median survival [18].…”